Adriana Guana

674 total citations
25 papers, 497 citations indexed

About

Adriana Guana is a scholar working on Dermatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Adriana Guana has authored 25 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Dermatology, 15 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Adriana Guana's work include Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (12 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Adriana Guana is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (12 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Adriana Guana collaborates with scholars based in United States, Switzerland and Canada. Adriana Guana's co-authors include David J. Goldberg, Leonard H. Goldberg, Xiangyi Meng, Carlos A. Camargo, I. Gilloteau, Judit Nyirady, Mark Lebwohl, Diamant Thaçi, Yang Zhao and L. Puig and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Adriana Guana

24 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adriana Guana United States	16	348	260	86	69	59	25	497
Bernadett Hídvégi Hungary	12	238 0.7×	154 0.6×	101 1.2×	95 1.4×	67 1.1×	38	471
H.M. Ockenfels Germany	15	336 1.0×	235 0.9×	54 0.6×	57 0.8×	52 0.9×	33	519
Irina Turchin Canada	13	256 0.7×	170 0.7×	51 0.6×	64 0.9×	83 1.4×	44	424
C. Spehr Germany	10	306 0.9×	319 1.2×	37 0.4×	39 0.6×	110 1.9×	13	547
María Jones‐Caballero Spain	14	360 1.0×	140 0.5×	79 0.9×	23 0.3×	157 2.7×	27	567
M.‐L. Sigal France	13	183 0.5×	235 0.9×	70 0.8×	16 0.2×	68 1.2×	64	519
H. Cameron United Kingdom	15	352 1.0×	254 1.0×	39 0.5×	59 0.9×	59 1.0×	19	546
Nisha Suyien Chandran Singapore	16	338 1.0×	81 0.3×	75 0.9×	77 1.1×	115 1.9×	74	596
Wayne Carey Canada	12	383 1.1×	153 0.6×	60 0.7×	17 0.2×	167 2.8×	36	649
Angela Patrì Italy	9	162 0.5×	158 0.6×	33 0.4×	17 0.2×	40 0.7×	33	333

Countries citing papers authored by Adriana Guana

Since Specialization

Citations

This map shows the geographic impact of Adriana Guana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriana Guana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriana Guana more than expected).

Fields of papers citing papers by Adriana Guana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriana Guana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriana Guana. The network helps show where Adriana Guana may publish in the future.

Co-authorship network of co-authors of Adriana Guana

This figure shows the co-authorship network connecting the top 25 collaborators of Adriana Guana. A scholar is included among the top collaborators of Adriana Guana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriana Guana. Adriana Guana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simpson, Eric L., Emma Guttman‐Yassky, Lawrence F. Eichenfield, et al.. (2023). Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition. Allergy. 78(11). 2875–2891. 21 indexed citations

Duffin, Kristina Callis, Marc A. Mason, Kenneth B. Gordon, et al.. (2020). Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology. 237(1). 46–55. 27 indexed citations

Voorhees, Abby S. Van, Marc A. Mason, Leslie R. Harrold, et al.. (2020). Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. Journal of Dermatological Treatment. 32(8). 907–915. 2 indexed citations

Voorhees, Abby S. Van, Marc A. Mason, Leslie R. Harrold, et al.. (2019). Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Journal of Dermatological Treatment. 32(3). 302–309. 16 indexed citations

Strober, Bruce, Rebecca Germino, Adriana Guana, et al.. (2019). US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Journal of Dermatological Treatment. 31(4). 333–341. 21 indexed citations

Poulos, Christine, Steven R. Feldman, I. Gilloteau, et al.. (2018). PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS’ TREATMENT CHOICE: A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US. Value in Health. 21. S434–S435. 1 indexed citations

Blauvelt, Andrew, April W. Armstrong, Renata M. Kisa, et al.. (2018). Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 2. S19–S19.

Pariser, David M., Ellen Frankel, Joel Schlessinger, et al.. (2017). Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy. 8(1). 17–32. 15 indexed citations

Sofen, Howard, et al.. (2017). Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Advances in Therapy. 34(6). 1327–1339. 24 indexed citations

10.

Bissonnette, Robert, Thomas A. Luger, Diamant Thaçi, et al.. (2017). Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. British Journal of Dermatology. 177(4). 1033–1042. 55 indexed citations

11.

Puig, L., Matthias Augustin, Andrew Blauvelt, et al.. (2017). Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. Journal of the American Academy of Dermatology. 78(4). 741–748. 25 indexed citations

12.

Blauvelt, Andrew, Kristian Reich, Stephanie Mehlis, et al.. (2017). Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study. Journal of the European Academy of Dermatology and Venereology. 31(10). 1693–1699. 19 indexed citations

13.

Kircik, Leon, Joseph F. Fowler, Jonathan Weiss, et al.. (2016). Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy. 6(4). 627–638. 20 indexed citations

14.

Armstrong, April W., Steven R. Feldman, Neil J. Korman, et al.. (2016). Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment. 28(3). 200–205. 14 indexed citations

15.

Menter, Alan, Jennifer Clay Cather, Michael Jarratt, et al.. (2016). Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy. 6(4). 639–647. 15 indexed citations

16.

Camargo, Carlos A., Adriana Guana, Sheldon Wang, & F. Estelle R. Simons. (2013). Auvi-Q Versus EpiPen: Preferences of Adults, Caregivers, and Children. The Journal of Allergy and Clinical Immunology In Practice. 1(3). 266–272.e3. 25 indexed citations

17.

Guana, Adriana, et al.. (1994). BASAL CELL CARCINOMA ON THE NAILEOLD OE THE RIGHT THUMB. International Journal of Dermatology. 33(3). 204–205. 14 indexed citations

18.

Guana, Adriana, et al.. (1994). Transient acantholytic dermatosis in oncology patients.. Journal of Clinical Oncology. 12(8). 1703–1709. 40 indexed citations

19.

Goldberg, Leonard H., et al.. (1994). TREATMENT OE A RECURRENT KERATOACANTHOMA WITH ORAL ISOTRETINOIN. International Journal of Dermatology. 33(8). 579–583. 18 indexed citations

20.

Guana, Adriana, et al.. (1993). AGGRESSIVE TRICHOEPITHELIOMA VERSUS KERATOTIC BASAL CELL CARCINOMA. International Journal of Dermatology. 32(10). 728–730. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact